Orasis Launches Presbyopia Eyedrop Qlosi in the US

Orasis Pharmaceuticals announced that Qlosi (pilocarpine hydrochloride ophthalmic solution) 0.4%, a novel, corrective prescription eye drop for the treatment of presbyopia in adults is now available to prescribe in the US. 

Qlosi’s proprietary 'EyeQ Formulation' is designed to maximize efficacy while minimizing side effects by balancing the lowest approved concentration of pilocarpine at a near neutral pH for optimal bioavailability, is preservative-free in single-use vials, and includes lubricants (HA & HPMC) for comfort. Patients have the flexibility of using one drop of Qlosi in each eye for improved near vision for a specific occasion or activity, and up to two drops per day for an extended effect, lasting up to 8 hours.

Read more.